Pharmaceutical

Rgenta Therapeutics’ RGT-61159 gains IND approval to treat cancers

Rgenta has secured approval for its IND application for RGT-61159, an oral small molecule RNA modulator, to treat cancers.

Jul 12, 2024 - 04:00
Rgenta Therapeutics’ RGT-61159 gains IND approval to treat cancers
Rgenta has secured approval for its IND application for RGT-61159, an oral small molecule RNA modulator, to treat cancers.
Read the original article

Tags:

Previous Article

Hong Kong approves Leqembi for Alzheimer’s treatment

Next Article

HarvestHub app tackles supply chain, food insecurity issues

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

AMA urges coverage of obesity treatments as payers balk at costs

AMA urges coverage of obesity treatments as payers balk...

Nov 13, 2023

STAT+: Pharmalittle: We’re reading about weight loss drugs, a cell therapy for melanoma, and more

STAT+: Pharmalittle: We’re reading about weight loss dr...

Feb 21, 2024

Regeneron gene therapy improves hearing in child

Regeneron gene therapy improves hearing in child

Oct 28, 2023